CG Oncology, Inc. (NASDAQ:CGON) Receives $63.88 Consensus Target Price from Analysts

CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) has been assigned an average recommendation of "Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $63.88.

A number of research analysts have recently weighed in on CGON shares. UBS Group assumed coverage on CG Oncology in a research note on Thursday, October 24th. They issued a "buy" rating and a $60.00 price target on the stock. Royal Bank of Canada began coverage on CG Oncology in a report on Monday, September 23rd. They set an "outperform" rating and a $66.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $75.00 price target on shares of CG Oncology in a research note on Tuesday, September 17th. Bank of America reissued a "buy" rating and set a $65.00 price objective on shares of CG Oncology in a research note on Tuesday, October 8th. Finally, Roth Mkm started coverage on shares of CG Oncology in a research note on Tuesday, August 27th. They issued a "buy" rating and a $65.00 target price for the company.

CG Oncology Stock Performance

CG Oncology stock traded up $0.88 during trading hours on Friday, reaching $39.94. 279,002 shares of the company's stock traded hands, compared to its average volume of 367,068. CG Oncology has a fifty-two week low of $25.77 and a fifty-two week high of $50.23. The firm's 50 day moving average is $36.78 and its 200-day moving average is $34.80.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.14. The business had revenue of $0.11 million during the quarter. Equities analysts anticipate that CG Oncology will post -1.45 earnings per share for the current year.

Insider Activity at CG Oncology

In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $35.36, for a total transaction of $23,000,088.80. Following the completion of the transaction, the director now owns 586,982 shares in the company, valued at approximately $20,755,683.52. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Hedge Funds Weigh In On CG Oncology

A number of large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets bought a new stake in CG Oncology during the 1st quarter worth about $492,000. Vanguard Group Inc. acquired a new stake in shares of CG Oncology in the first quarter valued at about $97,678,000. Ameritas Investment Partners Inc. bought a new stake in CG Oncology during the first quarter worth about $102,000. American International Group Inc. acquired a new position in CG Oncology during the first quarter valued at approximately $13,443,000. Finally, Decheng Capital LLC acquired a new position in shares of CG Oncology during the 1st quarter worth approximately $239,642,000. Institutional investors and hedge funds own 26.56% of the company's stock.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.